At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 208 enrolled
Drug / intervention
Rivastigmine 5 and 10 cm^2 patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)
In Brief
A Phase 4 clinical trial evaluating Rivastigmine 5 and 10 cm^2 patch for Alzheimer's Disease. Completed, enrolled 208 participants across 1 site.
Detailed Summary
This study evaluated the safety and efficacy of 10 cm\^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm\^2 for at least 8 weeks. This proportion was then compared to historical data of the percentage of patients who could reach a rivastigmine capsule target dose of 12 mg and stay on it at least 8 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedNov 21, 2007
Enrollment StartNov 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.6 years ago
Interventions
Rivastigmine 5 and 10 cm^2 patchdrug